<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cefbuperazone (CBPZ) was administered to patients with severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicating <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> to assess its efficacy and safety under such clinical conditions </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">Primary diseases</z:e> in this series of 78 cases included; <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in 41 cases, <z:hpo ids='HP_0005558'>chronic leukemia</z:hpo> in 6 cases, other <z:hpo ids='HP_0001909'>leukemia</z:hpo> in 9 cases, malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 13 cases, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> in 3 cases, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in 5 cases and 1 other case </plain></SENT>
<SENT sid="2" pm="."><plain>Types of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> included <z:hpo ids='HP_0100806'>sepsis</z:hpo>; proven or suspected, in 59 cases, <z:hpo ids='HP_0006532'>pulmonary infection</z:hpo> in 8 cases, upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> in 5 cases, and other cases </plain></SENT>
<SENT sid="3" pm="."><plain>CBPZ was infused by an intravenous drip method at a dosage of 4-8 g daily </plain></SENT>
<SENT sid="4" pm="."><plain>Patients' ages ranged from 14 to 85 years </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical response to the CBPZ regimen was excellent in 24 cases, good in 22 cases, fair in 2 cases, and poor in 30 cases </plain></SENT>
<SENT sid="6" pm="."><plain>Thus the overall efficacy rate (percentage of cases showing an excellent or good response) was 59.0% </plain></SENT>
<SENT sid="7" pm="."><plain>Efficacy rates for individual types of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> were: documented <z:hpo ids='HP_0100806'>sepsis</z:hpo> 16.7%, suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo> 58.5%, lower <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> 62.5%, and upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> 100% </plain></SENT>
<SENT sid="8" pm="."><plain>CBPZ also proved to be effective in 61.0% of cases with a neutrophil count of less than 500/mm3 prior to therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Side effects encountered were <z:hpo ids='HP_0002014'>diarrhea</z:hpo> in 1 case, gastric discomfort in 1 case and hepatic dysfunction in 5 cases </plain></SENT>
<SENT sid="10" pm="."><plain>These side effects, however, were not dose-related, and none were serious </plain></SENT>
<SENT sid="11" pm="."><plain>These results indicate that CBPZ has a high therapeutic efficacy even in patient with compromised immunodefenses </plain></SENT>
</text></document>